Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Wyeth diet drug settlement

Executive Summary

Wyeth will evaluate the number of Redux patients that opt into proposed amendment to the class action diet drug settlement agreement before determining whether it needs to take additional legal reserves. The so-called "Seventh Amendment" creates a $1.275 bil. fund for fen/phen patients with less serious medical conditions. The amendment would allow Wyeth to expedite reduced settlements for 40,000 patients, and leave what remains of the original $3.75 bil. trust for fen/phen patients with more serious health problems. Wyeth will make initial payments of up to $50 mil. to begin reviewing claims. Following court approval, the company will make a $400 mil. payment to begin paying claims. Wyeth has taken $16.6 bil. in fen/phen-related charges to date and has $3.26 bil. in reserves...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS044524

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel